To obtain a new acridone-based compound having activity to inhibit binding of IgE receptor γ-chain to tylosin kinase at 72 kDa, thus useful for preventing/treating asthma, allergic rhinitis, atopic rhinitis, nettle rash, etc.
This new compound is an acridone derivative (pharmacologically permissible salt thereof) of formula I {R1 to R6 are each H, OH, cyano, nitro, amino, a halogen, lower alkyl, lower alkoxy, etc.; Y is a group of the formula A-Z [A is of the formula (CH2)t-(B)m-(CH2)n ((m) is 0 or 1; (t) and (n) are each an integer or 0-6; B is a lower alkylene, etc.); Z is cyano, carboxyl, etc.]; D is 0 atom or S atom}, e.g. 10-(3-aminopropyl)-8-carboxymethyl-3,4-dimethyl-9- acridone n-heptyl ester. The compound of formula I is obtained by cyclizing a carboxydiphenylamine formed by Ullman reaction into a compound of formula II which is, in turn, subjected to condensation reaction, Gabriel synthesis, etc.
YOSHIUCHI TATSUYA
SATO KEIZO
KAINO MASATO
TAKASHIMA YOSHIHIRO
MORIYA KATSUHIRO
SAKUMA YOSHINORI
YAMADA KOJI
HARADA KOKICHI
NISHIZAWA YUKIO
KOBAYASHI SEIICHI
OKITA MAKOTO
KATAYAMA KOICHI